Korro Bio (KRRO) filed a registration statement Monday with the US Securities and Exchange Commission covering the potential sale of up to $400 million of its securities from time to time.
The filing covers a base prospectus for up to $400 million of debt securities, common stock, preferred stock, units, and warrants in one or more offerings, including an "at the market offering" of up to $100 million of common shares under a sales agreement with TD Securities.
Proceeds will be used for general corporate purposes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。